Share Name Share Symbol Market Type Share ISIN Share Description
GlaxoSmithKline LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00p -0.63% 1,566.00p 1,565.80p 1,566.20p 1,581.40p 1,565.20p 1,581.40p 869,355 09:27:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,186.0 3,525.0 31.4 49.9 77,671.52

GlaxoSmithKline Sells Tapinarof Rights for Up to GBP250 Million

12/07/2018 3:35pm

Dow Jones News

GlaxoSmithKline (LSE:GSK)
Historical Stock Chart

1 Month : From Jun 2018 to Jul 2018

Click Here for more GlaxoSmithKline Charts.

By Carlo Martuscelli


GlaxoSmithKline PLC (GSK.LN) said Thursday that it had sold the rights to its drug candidate tapinarof for up to 250 million pounds ($331 million) to Roivant Sciences.

The pharmaceutical major said that the deal includes an initial payment of GBP150 million plus a potential future milestone payment of GBP100 million.

Roivant will acquire the rights for the drug worldwide, with the exception of China, GSK said.

"We have taken a strategic decision to divest or partner medicines in our R&D portfolio that are a better fit for other companies, allowing us to concentrate our resources on other promising assets," said John Lepore, senior vice president, R&D pipeline at GSK.

Tapinarof is a drug being developed for the treatment of psoriasis and atopic dermatitis.


Write to Carlo Martuscelli at


(END) Dow Jones Newswires

July 12, 2018 10:20 ET (14:20 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

1 Year GlaxoSmithKline Chart

1 Year GlaxoSmithKline Chart

1 Month GlaxoSmithKline Chart

1 Month GlaxoSmithKline Chart
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V:gb D:20180716 08:42:37